Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.

Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg C, Putora PM.

Oncologist. 2015 Sep;20(9):1028-35. doi: 10.1634/theoncologist.2015-0145. Epub 2015 Aug 3.

2.

Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms.

Rothermundt C, von Rappard J, Eisen T, Escudier B, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg CN, Putora PM.

World J Urol. 2017 Apr;35(4):641-648. doi: 10.1007/s00345-016-1903-6. Epub 2016 Aug 3.

PMID:
27488984
3.

Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era.

Gravis G, Chanez B, Derosa L, Beuselinck B, Barthelemy P, Laguerre B, Brachet PE, Joly F, Escudier B, Harrison DJ, Laird A, Vasudev N, Ralph C, Larkin J, Lote H, Salem N, Walz J, Thomassin J, Sfumato P, Stewart GD, Boher JM; Renal Cross Channel Group.

Urol Oncol. 2016 Apr;34(4):167.e17-23. doi: 10.1016/j.urolonc.2015.10.015. Epub 2015 Dec 3.

PMID:
26670200
4.

First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.

Takyar S, Diaz J, Sehgal M, Sapunar F, Pandha H.

Anticancer Drugs. 2016 Jun;27(5):383-97. doi: 10.1097/CAD.0000000000000335. Review.

PMID:
26886011
5.

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

Miller K, Bergmann L, Gschwend J, Keilholz U, Kuczyk M.

Aktuelle Urol. 2014 Jan;45(1):39-44. doi: 10.1055/s-0033-1363228. Epub 2014 Feb 5. Review. German.

PMID:
24500960
6.

Targeted Therapy for Metastatic Renal Cell Carcinoma.

Afriansyah A, Hamid AR, Mochtar CA, Umbas R.

Acta Med Indones. 2016 Oct;48(4):335-347. Review.

7.

[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].

Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend J, Kuczyk M.

Aktuelle Urol. 2015 Mar;46(2):151-7. doi: 10.1055/s-0035-1547281. Epub 2015 Apr 21. Review. German.

PMID:
25897537
9.

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K.

Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv. doi: 10.3310/hta14020. Review.

10.

Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.

Levy A, Menard J, Albiges L, Loriot Y, Di Palma M, Fizazi K, Escudier B.

Eur J Cancer. 2013 May;49(8):1898-904. doi: 10.1016/j.ejca.2013.02.003. Epub 2013 Mar 13.

PMID:
23490648
11.

Tolerability of first-line therapy for metastatic renal cell carcinoma.

Porta C, Szczylik C.

Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26. Review.

PMID:
19249157
12.

Optimal management of metastatic renal cell carcinoma: an algorithm for treatment.

Bellmunt J, Flodgren P, Roigas J, Oudard S.

BJU Int. 2009 Jul;104(1):10-8. doi: 10.1111/j.1464-410X.2009.08563.x. Epub 2009 Apr 21. Review.

13.

GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer.

Bracarda S, Sisani M, Marrocolo F, Hamzaj A, del Buono S, De Simone V.

Crit Rev Oncol Hematol. 2014 Mar;89(3):386-93. doi: 10.1016/j.critrevonc.2013.09.002. Epub 2013 Nov 13. Review.

PMID:
24309065
14.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

15.

First-line treatment result influence second-line regimen selection in targeted therapy for metastatic renal cell carcinoma.

Li JR, Yang CK, Wang SS, Chen CS, Chiu KY, Cheng CL, Yang CR, Ho HC, Ko JL, Ou YC.

Anticancer Res. 2014 Oct;34(10):5643-7.

PMID:
25275068
16.

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, Hainsworth JD, Kollmannsberger CK, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ.

Lancet Oncol. 2016 Mar;17(3):378-88. doi: 10.1016/S1470-2045(15)00515-X. Epub 2016 Jan 13.

PMID:
26794930
17.

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.

Eur Urol. 2015 Nov;68(5):837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4.

18.

Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.

Ainsworth NL, Lee JS, Eisen T.

Expert Rev Anticancer Ther. 2009 Dec;9(12):1793-805. doi: 10.1586/era.09.144. Review.

PMID:
19954291
19.

Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.

Schmidinger M, Zielinski CC.

Cancer Treat Rev. 2009 May;35(3):289-96. doi: 10.1016/j.ctrv.2009.01.004. Epub 2009 Feb 15. Review.

PMID:
19232474
20.

ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.

Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J.

Eur Urol. 2011 Oct;60(4):684-90. doi: 10.1016/j.eururo.2011.06.017. Epub 2011 Jun 24. Review.

PMID:
21704448

Supplemental Content

Support Center